Orexo AB (publ.) announced the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking. During the last year, Orexo and Trinity Health have collaborated to establish new administrative processes and support systems to ensure effective patient access to these innovative digital therapies and reimbursement of the products through a collaborative care model.

In preparation for the implementation, Orexo and Trinity Health have educated more than 50 healthcare professionals in the collaborative care model, where more traditional healthcare delivery methods are combined with Orexo's digital therapies. To ensure successful implementation, Orexo and Trinity Health have agreed on an extensive communication plan to patients in North Dakota and Eastern Montana. Both vorvida® and deprexis® are based on cognitive behavioural therapy techniques that empower patients in their efforts to make behaviour and lifestyle changes.

These digital therapeutics can be used privately and are available 24 hours a day, helping to reduce the stigma that is often associated with mental illness and substance use disorders (SUD) as well as making evidence-based psychosocial support accessible to a large group of patients.